ClinicalTrials.gg
CompletedNCT07855471DOM-HFUpdated Oct 2, 2026

Heart Failure Telemonitoring Across French Overseas Departments and Mainland France

An observational study in Heart Failure, sponsored by Satelia. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Satelia · Observational

How we know

Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
32,380
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 448 studies in Heart Failure with a site in France — 90 open to participants now, 116 under way, 16 of them phase 3. Heart Failure · France.

Enrollment
3rd of 161
32,380 · median 321
Started
2018
with 27 others
Observational
161 of 448
28 open now
Registered
448th of 448
by date

Among the 448 studies in Heart Failure with a site in France, this one is the 3rd largest by enrollment of the 161 observational ones that give a count, is one of 28 that started in 2018, is one of 161 observational ones, and was the 448th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

90 of the 448 studies in Heart Failure with a site in France are open now. Recruiting first, the newest first:

85 more — sign in →

All 90 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 448 studies in Heart Failure with a site in France, or all of them as a file.
02

Study summary

This retrospective, multicenter observational cohort study evaluates adults with heart failure enrolled in the Satelia® Cardio telemonitoring program in France between 28 August 2018 and 6 July 2026. Participants are classified according to the location of their follow-up center into a French overseas departments cohort, comprising Martinique, Guadeloupe, and La Réunion, and a mainland France cohort. The study evaluates regional differences in clinical characteristics, telemonitoring organization and engagement, guideline-directed medical therapy (GDMT) use, and follow-up status.

Read the detailed description

This study is a retrospective, multicenter comparative cohort analysis based on routinely collected data from the Satelia® Cardio heart failure telemonitoring program. All adult patients with heart failure enrolled in the program between 28 August 2018 and 6 July 2026 were eligible for inclusion. Participants are categorized according to the geographic location of the center responsible for their follow-up. The overseas cohort comprises patients followed in ten centers across Martinique, Guadeloupe, and La Réunion, while the comparison cohort comprises patients followed in mainland France. Patients whose follow-up center could not be determined were excluded, leaving 32,380 patients for analysis.

Variables assessed include age, sex, NYHA functional class, LVEF, heart failure etiology, cardiovascular risk factors and comorbidities, monitoring mode and frequency, questionnaire adherence, triggered alerts, duration of follow-up, guideline-directed medical therapy, follow-up status, and reasons for discontinuation. Guideline-directed medical therapy is evaluated according to therapeutic class, including beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor-neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors. Patients are considered exposed to a therapeutic class if at least one prescription for that class was recorded at any time during follow-up. Three-class and four-class GDMT are also assessed; four-class GDMT denotes recorded exposure to all four foundational treatment classes and does not require documented simultaneous use at a single time point. Analyses of NYHA class, LVEF, and heart failure etiology are restricted to participants with available data. Guideline-directed medical therapy is additionally assessed according to left ventricular ejection fraction category.

03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • telemonitoring
  • remote patient monitoring
  • French overseas territories
  • guideline-directed medical therapy
  • left ventricular ejection fraction
  • health equity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with heart failure enrolled in the Satelia® Cardio telemonitoring program in France between 28 August 2018 and 6 July 2026. Participants were classified according to the location of the center responsible for their follow-up as either the French overseas departments cohort, comprising Martinique, Guadeloupe, and La Réunion, or the mainland France cohort.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older.
  • Diagnosis of heart failure.
  • Enrollment in the Satelia® Cardio telemonitoring program between 28 August 2018 and 6 July 2026.
  • Follow-up by a participating center in either the French overseas departments of Martinique, Guadeloupe, or La Réunion, or mainland France.

Exclusion criteria

Exclusion Criteria:

- Follow-up center could not be determined from the extracted data.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
32,380 participants (actual)
Patient registry
No

Groups and cohorts

  • French Overseas Territories (DOM)

    Adults with heart failure enrolled in the Satelia Cardio remote monitoring program and followed by one of nine participating centers located in Martinique, Guadeloupe, or La Réunion.

  • Mainland France

    Adults with heart failure enrolled in the Satelia Cardio remote monitoring program and followed by participating centers located in mainland France.

06

What researchers measure

Primary outcomes

  1. Clinical Profile of Participants by Geographic Cohort

    Demographic and clinical characteristics of participants in the French overseas departments and mainland France cohorts, including age, sex, New York Heart Association functional class, left ventricular ejection fraction category, heart failure etiology, cardiovascular risk factors, and comorbidities.

    Time frame: At enrollment in the Satelia Cardio remote monitoring program

  2. Telemonitoring Organization and Engagement by Geographic Cohort

    Telemonitoring organization and engagement, including monitoring mode, monitoring frequency, questionnaire adherence, triggered clinical alerts, and duration of follow-up, compared between the French overseas departments and mainland France cohorts.

    Time frame: From enrollment through the end of follow-up, up to 6 July 2026.

  3. Guideline-Directed Medical Therapy Exposure by Geographic Cohort

    Proportion of participants with recorded exposure to beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, angiotensin receptor-neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors. Exposure to a therapeutic class is defined as at least one prescription for that class recorded at any time during follow-up. Three-class and four-class GDMT are also assessed, with four-class GDMT defined as recorded exposure to beta-blocker, renin-angiotensin system inhibition (ARNI, ACEi, or ARB), MRA, and SGLT2i; concurrent use at a single time point is not required.

    Time frame: During telemonitoring follow-up, through 6 July 2026

  4. Retention Under Telemonitoring and Reasons for Discontinuation

    Proportion of participants remaining under telemonitoring at the end of follow-up and distribution of recorded reasons for discontinuation, including death, patient-initiated discontinuation, and care-team-initiated discontinuation.

    Time frame: Status at the end of follow-up, through 6 July 2026.

Secondary outcomes

  1. Guideline-Directed Medical Therapy by Left Ventricular Ejection Fraction Category

    Guideline-directed medical therapy exposure assessed within reduced left ventricular ejection fraction (\<40%), mildly reduced left ventricular ejection fraction (40-49%), and preserved left ventricular ejection fraction (≥50%) categories. GDMT exposure is based on recorded prescriptions during follow-up.

    Time frame: During telemonitoring follow-up, through 6 July 2026.

07

Study locations

1 site
  • NP Médical / Satelia
    Bordeaux, Nouvelle-Aquitane 33000, France
08

References and documents

Publications

  • Girerd N, Barbet V, Seronde MF, Benchimol H, Jagu A, Tartiere JM, Hanon O, Picard F, Lafitte S, Lemaitre M, Pages N, Nisse-Durgeat S, Jourdain P. Association of a remote monitoring programme with all-cause mortality and hospitalizations in patients with heart failure: National-scale, real-world evidence from a 3-year propensity score analysis of the TELESAT-HF study. Eur J Heart Fail. 2025 Sep;27(9):1658-1669. doi: 10.1002/ejhf.3563. Epub 2025 Jan 14. PubMed 39807086 ↗
  • Monzo L, Hanon O, Savarese G, Fauvel C, Berthelot E, Seronde MF, Assyag P, Esser R, Picard F, Pages N, Nisse-Durgeat S, Girerd N. Temporal trends and factors associated with SGLT2 inhibitor prescription in a nationwide French heart failure remote monitoring program. Int J Cardiol. 2026 Jul 21;462:134683. doi: 10.1016/j.ijcard.2026.134683. Online ahead of print. PubMed 42480823 ↗

Individual participant data

Plan to share: No — Individual participant-level data will not be made publicly available because the study is based on pseudonymised routine-care health data subject to applicable data-protection and governance requirements.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Jul 2026, 94 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 2, 2026
StartActual
Aug 28, 2018
Primary completionActual
Jul 6, 2026
CompletionActual
Jul 6, 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07855471
Lead sponsor
Satelia
Collaborators
University Hospital Center of Martinique
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Aug 28, 2018
Primary completion
Jul 6, 2026
Completion
Jul 6, 2026
Last update
Oct 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion